Effect of menatetrenone on bone mineral density and incidence of vertebral fractures in postmenopausal women with osteoporosis: a comparison with the effect of etidronate

https://doi.org/10.1007/s007760100002Get rights and content

Abstract

The purpose of the present study was to compare the effects of etidronate and menatetrenone on bone mineral density (BMD) and the incidence of vertebral fractures in postmenopausal women with osteoporosis. Seventy-two osteoporotic women, more than 5 years after menopause, 53–78 years of age, were randomly divided into three administration groups: E group; intermittent cyclical etidronate (200 mg/day, 14 days per 3 months; n = 25); M group; menatetrenone (45 mg/day, daily; n = 23); and C group (control); calcium lactate (2 g/day, daily; n = 24). Forearm BMD was measured by dual-energy X-ray absorptiometry at 0, 6, 12, 18, and 24 months after the treatment started. There were no significant differences in age, body mass index, years since menopause, and initial BMD among the three groups. One-way analysis of variance (ANOVA) with repeated measurements showed a significant decrease in BMD in the C group (P < 0.0001). Two-way ANOVA with repeated measurements showed a significant increase in BMD in the M group compared with that in the C group (P < 0.0001), and a significant increase in BMD in the E group compared with that in the C and M groups (P < 0.0001 and P < 0.01, respectively). The indices of new vertebral fractures/1000 patient-years in the E and M groups were significantly higher than that in the C group (χ2 = 47.7; P < 0.0001 and χ2 = 42.4; P < 0.0001, respectively), and did not differ significantly between the E and M groups. The present preliminary study provides evidence to suggest that, despite the lower increase in BMD produced by menatetrenone, this agent, as well as etidronate, may have the potential to reduce osteoporotic vertebral fractures in postmenopausal women with osteoporosis.

References (38)

  • S.J. Wimalawansa

    A 4-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis

    Am J Med

    (1998)
  • P. Bettica et al.

    Short-term variations in bone remodeling biochemical markers: cyclical etidronate and alendronate effects compared

    J Clin Endocrinol Metab

    (1997)
  • C.H. Chesnut

    Osteoporosis and its treatment

    N Engl J Med

    (1992)
  • R.G. Cumming

    Calcium intake and bone mass: a quantitative review of the evidence

    Calcif Tissue Int

    (1990)
  • T. Fujita

    Clinical guidelines for the treatment of osteoporosis in Japan

    Calcif Tissue Int

    (1996)
  • T. Fujita et al.

    A 3-year comparative trial in osteoporosis treatment: effect of combined alfacalcidol and elcatonin

    J Bone Miner Metab

    (1997)
  • M.-H. Gannage-Yared et al.

    Hypovitaminosis D in a sunny country: relation to lifestyle and bone markers

    J Bone Miner Res

    (2000)
  • A. Gürlek et al.

    Comparison of calcitriol treatment with etidronate-calcitriol and calcitonin-calcitriol combinations in Turkish women with postmenopausal osteoporosis: a prospective study

    Calcif Tissue Int

    (1997)
  • K. Hara et al.

    Menatetrenone inhibits bone resorption partly through inhibition of PG E2 synthesis in vitro

    J Bone Miner Res

    (1993)
  • Cited by (72)

    • Effects of vitamin K in postmenopausal women: Mini review

      2014, Maturitas
      Citation Excerpt :

      None of these three studies evaluated the fracture risk. Isolated effects of MK-4 vs placebo or calcium were evaluated in six RCTs [8–11,13,14]. Molecular improvements were assessed in four of these studies [8,11,13,14]; and improvement on OC was detected in all four studies; however, there are inconsistent results on BAP, NTX, and urinary markers.

    • Nutrition and Risk for Osteoporosis

      2013, Osteoporosis: Fourth Edition
    • Intake of vitamin K1 and K2 and risk of hip fractures: The Hordaland Health Study

      2011, Bone
      Citation Excerpt :

      No RCTs have been a priori designed to show a difference in hip fractures as the main outcome. In two different studies comparing treatment with menatetrenone (a vitamin K2) to placebo, the treatment groups had fewer vertebral fractures during 2 years of follow-up than controls [35,36]. In a study comparing the fracture preventive effect of calcium compared to calcium and menatetrenone supplementation combined, no difference was found between the groups regarding incidence of clinical fractures (humeral, femoral, radial and high-trauma vertebral fractures) [37].

    • Vitamin K: Infection, Inflammation, and Auto-Immunity

      2024, Journal of Inflammation Research
    View all citing articles on Scopus
    View full text